17 th Biennial IAGS Meeting Chiang Rai, Thailand: January 30 — February 2, 2024 Preliminary Program Agenda (Page 1 of 4)					
				senters / Chairs /	Panelists / Audience:
		on & Recommendat			
	knowledge / data (5 min)	How to r	resolve gaps / Bring	<mark>clinical topic to clo</mark>	osure (20 min)
Day 1	Tuesday, January 30, 2024				
0715-0730	Introduction and Welcome		Chairs: Robert Bersin & Gary Roubin		
0730-0900	Session #1: Coronary Session 1 - Elective PCI				
	Topics		Problem Presenters	Chairs	Panelists
0730-0800	DCB's for De Novo Coronary Le Are We There Yet?	esions:			
0800-0830	Plaque Modification: When to Apply Ablative vs. Disruptive Therapies				
0830-0900	The Ignored Side Branch of Bifurcation Lesions: Are Side Branch Birfurcation DES's or DCB's the Answer?				
0900-0915	Break				
0915-1045	Session #2: Structural Session 1 - Aortic Valve				
	Topics		Problem Presenters	Chairs	Panelists
0915-0945	TAVR for Aortic Insufficiency: L Devices and Do We Have "Suff Evidence?				
0945-1015	Lifelong TAVR Durability: How With Leaflet Degeneration	to Deal			
1015-1045	TAVR for Moderate AS: Not So Fast				
1045-1100	Break				
1100-1230	Session #3: Endovascular Sess	ion 1			
	Topics		Problem Presenters	Chairs	Panelists
1100-1130	DCB's, Stents and Endografts in Extremity Interventions: What Leave Nothing Behind or a Less Specific Approach?	is Best?			
1130-1200	Endografts for Aortic Aneurysr do They ADVANCE? Stay In Bou Pay the Price? Suprarenal vs. Infrarenal Grafts?				
1200-1230	Carotid Artery Intervention: Comparative Outcomes of Mic Stents and TCAR and are they than CEA?				
1230-1330	Luncheon Symposium: Elective PCI / Aortic Valve / Endovascular		Chairs:		

17 th Biennial IAGS Meeting Chiang Rai, Thailand: January 30 – February 2, 2024						
			Agenda (Page 2 of 4)	2024		
Instructions for Problem Presenters: Instructions for Problem Presenters / Chairs / Panelists / Audie					Panelists / Audience:	
State the status of our knowledge (5 min)			sion & Recommendat			
List the gaps in our knowledge / data (5 min) How to resolve gaps / Bring clinical topic to closure (20 min)						
Day 2	Wednesday, January 31, 2024					
0715-0730	Recap of Previous Day and Announcements		Chairs: Robert Bers	airs: Robert Bersin & Gary Roubin		
0730-0900	Session #4: Coronary Session 2 - S	ГЕМІ				
	Topics		Problem Presenters	Chairs	Panelists	
0730-0800	COMPLETE Revascularization Following STEMI: Not Whether, When					
0800-0830	Therapies to Minimize Myocardial Injury and Improve Microvascular Function During STEMI					
0830-0900	Interventional Pharmacology: Data Driven Best Practices					
0900-0915 Break						
0915-1045	Session #5: Structural Session 2 - Mitral and Tricuspid Valve					
	Topics		Problem Presenters	Chairs	Panelists	
0915-0945	Interventional Mitral Repair: Latest Annular Devices and Can they Deal with MAC?					
0945-1015	TMVR: Latest Transeptal Valves and Clinical Outcomes					
1015-1045	TEER vs. Tricuspid Valve Replacement: Where to go Following TRILUMINATE					
1045-1100	Break					
1100-1230 Session #6: Structural Session 3 – Atrial & Ventricular						
	Topics		Problem Presenters	Chairs	Panelists	
1100-1130	LAA Occlusion: Is the "Square Peg i					
	Round Hole" Problem Now Solved?			_		
1130-1200	Interventional Ventricular Remode Heart Failure	ling in				
	neart railure			_		

Chairs:

1200-1230

1230-1330

Interventional Electrocautery: Open

Luncheon Symposium: STEMI / Mitral & Tricuspid Valve / Atrial & Ventricular

SESAME

17th Biennial IAGS Meeting Chiang Rai, Thailand: January 30 - February 2, 2024

Preliminary Program Agenda (Page 3 of 4) **Instructions for Problem Presenters:** Instructions for Problem Presenters / Chairs / Panelists / Audience: State the status of our knowledge (5 min) **Discussion & Recommendations:** How to resolve gaps / Bring clinical topic to closure (20 min) List the gaps in our knowledge / data (5 min) Thursday, February 1, 2024 Day 3 0715-0730 Recap of Previous Day and Chairs: Robert Bersin & Gary Roubin Announcements 0730-0900 Session #7: Hemodynamics Session 1 Problem **Topics** Chairs **Panelists** Presenters 0730-0800 Circulatory Support for Complex, High Risk PCI: How to Predict Who Benefits 0800-0830 Circulatory Support for Cardiogenic Shock: Matching the Device Strategy to the Patient for Best Outcomes 0830-0900 Novel Devices and New Strategies for the Management of High Risk Pulmonary **Embolism** 0900-0915 Break 0915-1045 Session #8: Endovascular Session 2 Problem **Topics** Chairs **Panelists** Presenters Ultrasound Imaging for Endovascular 0915-0945 Interventions: A New Standard? 0945-1015 Bioresorbable Scaffolds for BTK Interventions: Are They the Answer or Just Another "Hail Mary" 1015-1045 BEST Approaches to Revascularization in Critical Limb Ischemia: Interventional or Surgical? 1045-1100 Break 1100-1230 Session #9: Emerging Therapies Session 1 Problem **Topics** Chairs **Panelists Presenters** 1100-1130 UHD and 3D Interventional Imaging 1130-1200 Renal Denervation: Comparison of Latest Therapeutic Approaches and Indications. Do we Need AUC Criteria? 1200-1230 Translational Research: Real Impact on Interventional Medicine? 1230-1330 Luncheon Symposium: Chairs:

Shark Tank Competition /

Emerging Therapies

Hemodynamics / Endovascular /

17 th Biennial IAGS Meeting						
	Chiang Rai, Thailan	ıd: Januaı	ry 30 – February 2, :	2024		
Preliminary Program Agenda (Page 4 of 4) Instructions for Problem Presenters: Instructions for Problem Presenters / Chairs / Panelists / Audience:						
			on & Recommendat		unclists / Addictice.	
List the gaps in our knowledge / data (5 min) How to resolve gaps / Bring clinical topic to closure (20 min)					sure (20 min)	
Day 4 Friday, February 2, 2024						
0715-0730	Recap of Previous Day and Announcements		Chairs: Robert Bersin & Gary Roubin			
0730-0900	Session #10: Coronary Session #3	Session #10: Coronary Session #3				
	Topics		Problem Presenters	Chairs	Panelists	
0730-0800	Invasive vs. Noninvasive Coronary Lesion Physiology: Who Should Get What and in Which Settings					
0800-0830	A Critical Appraisal of Intravascular Imaging: When Does it Really Matter?					
0830-0900	Latest Devices for CTO Intervention: Do They Improve Outcomes and Change Indications?					
0900-0915	Break					
0915-1045	Session #11: Health Care Delivery Session 1					
	Topics		Problem Presenters	Chairs	Panelists	
0915-0945	Artificial Intelligence in Interventio Medicine	Artificial Intelligence in Interventional Medicine				
0945-1015	Health Equity					
1015-1045	The Consequences of Public Reporting and Star Ratings					
1045-1100	Break					
1100-1200	IAGS Business Meeting					
1200-1300	Luncheon Symposium Coronary / Health Care Delivery		Chairs:			
1300	17 th Biennial IAGS Meeting Adjourn	ns				

Chiar	iial International Andreas Gruentzig Soci ng Rai, Thailand: January 30 – February i rticipant List <mark>(as of 6/17/2023 - Page 1</mark>	2, 2024
J. Dawn Abbott, MD, FACC, FSCAI Providence RI USA	Nicholas Amoroso, MD Charleston SC USA	H. Vernon (Skip) Anderson, MD, FSCAI Houston TX USA
Salman Arain, MD Houston TX USA	Herbert Aronow, MD, MPH, FACC, FSCAI, FSVM Detroit MI USA	Suzanne Baron, MD, MSc Burlington MA USA
Itsik Ben-Dor, MD	Robert M. Bersin, MD, FACC	Charles L. Brown, III, MD
Washington DC DC USA	Seattle WA USA	Atlanta GA USA
Mauricio Cohen, MD	David Alan Cox, MD	Megan CoyleWright, MD, MPH
Cleveland OH USA	Charlotte NC USA	Chattanooga TN USA
Eric Dippel, MD	Dmitriy Feldman, MD	Tim A. Fischell, MD, FSCAI
Davenport IA USA	New York NY USA	Kalamazoo MI USA
Santiago Garcia, MD, FACC, FSCAI	Kirk Garratt, MD, FSCAI	Ian C. Gilchrist, MD
Cincinnati OH USA	Stillwater MN USA	Hershey PA USA
Adam B. Greenbaum, MD	Cindy Grines, MD	George S. Hanzel, MD
Atlanta GA USA	Johns Creek GA USA	Atlanta GA USA
Tarek Helmy, MD, FACC, FSCAI Shreveport LA USA	Timothy Darrell Henry, MD, FACC, MSCAI Cincinnati OH USA	Jimmy Kerrigan, MD, FACC, FSCAI Nashville TN USA
Brian Kolski, MD, FACC	Nicholas J. Lembo, MD, FACC, FSCAI	Amir Lerman, MD
Costa Mesa CA USA	Alys Beach FL USA	Rochester MN USA
Ayman A. Magd, MD, PhD Cairo Egypt	J. Jeffrey Marshall, MD Gainesville GA USA	Sundeep Mishra, MD, DM, FACC, FSCAI New Delhi Delhi India
Michael Mooney, MD, FSCAI	Max Muhs,	Piotr Musialek, MD, Dphil
Eden Praire MN USA	Sydney Australia	Krakow Poland

Srihari S. Naidu, MD, FACC, FSCAI

William W. O'Neill, MD, FSCAI

Augusto Pichard, MD, FSCAI

Hawthorne NY USA

Detroit MI USA

Annapolis MD USA

Michael Rinaldi, MD

Charlotte NC USA

Sigrid Nikol, MD

La Jolla CA USA

Miami FL USA

Hamburg Germany

Ramon Quesada, MD

Toby Rogers, MD, PhD

Washington DC USA

Mitul P. Patel, MD, FACC, FSCAI

Jihad Mustapha, MD

Grand Rapids MI USA

Brian O'Murchu, MD

Philadelphia PA USA

New Orleans LA USA

Charanjit Rihal, MD

Rochester MN USA

Rajan Patel, MD

17 th Biennial International Andreas Gruentzig Society Meeting Chiang Rai, Thailand: January 30 – February 2, 2024 Participant List (as of 6/17/2023 - Page 2 of 2)					
Birmingham AL USA	Birmingham AL USA	Janar Sathananthan, MBChB Vancouver British Columbia Canada			
Jonathan G. Schwartz, MD, FACC, FSCAI Charlotte NC USA	Binita Shah, MD, MS New York NY USA	Rahul Sharma, MBBS Palo Alto CA USA			
Fayaz Shawl, MD, FSCAI Silver Sprint MD USA	Kimberly A. Skelding, MD, FACC, FAHA, FSCAI Wenatchee WA USA	Richard W. Smalling, MD, FSCAI Houston TX USA			
Molly Szerlip, MD Plano TX USA	Jacqueline Tamis-Holland, MD Cleveland OH USA	Charles Allen Thompson, MD Zachary LA USA			
Alexander G. Truesdell, MD, FACC, FSCAI McLean VA USA	Bonnie H. Weiner, MD, MSEC, MBA Harvard MA USA	R. Jeffrey Westcott, MD, FACC, FSCAI Maple Valley WA USA			
B. Hadley Wilson, MD Charlotte NC USA	David Wood, MD, FRCPC, FACC, FESC, FSCCT Vancouver BC Canada	James P. Zidar, MD, FACC, FSCAI Raleigh NC USA			

17th Biennial International Andreas Gruentzig Society Meeting Chiang Rai, Thailand: January 30 - February 2, 2024 Needs Assessment & Learning Objectives

The needs assessment and gaps in clinical practice were determined via the following process:

Our Program Director selected a program planning committee consisting of international leaders and experts in the following fields: Interventional cardiology, cardiac surgery, interventional radiology and vascular surgery. Knowledge gaps were identified from clinical trials, recent medical literature, surveys of past program participants, and through the IAGS membership as well as the program committee members' own experiences in current clinical practice. These gaps provide the foundation for the educational needs to be addressed during our meeting in the following areas of clinical practice:

- 1. Structural heart disease: Valve therapies for aortic, mitral and tricuspid valve diseases, long term management of leaflet degeneration following transcatheter valve replacements, atrial appendage occlusion, ventricular remodeling therapies and applications of interventional electrocautery in structural heart disease and hypertophic cardiomyopathies.
- 2. Coronary artery disease: Imaging, plaque characterization, non-stent interventions, best management of bifurcation lesions, STEMI revascularization, therapies to limit myocardial injury, and best interventional pharmacologic practices.
- 3. Peripheral vascular disease: Best applications of endovascular aneurysm repair, interventional therapies for carotid artery disease, infra-inguinal interventions, BTK drug delivery devices, interventional vs. surgical management of critical limb ischemia.
- 4. Emerging therapies: Renal denervation, advanced UHD and 3D imaging, and translational research in interventional medicine.
- 5. Hemodynamic support: Hemodynamic support devices in high risk PCI, device selection and combinations for treatment of cardiogenic shock, and new device strategies for high risk pulmonary embolism.

How will you ensure that the educational content is current, and based on best available evidence?:

Our faculty members are international experts on their assigned topics. Many of them are high level clinical investigators involved in cutting edge research. The program planning committee will work directly with the faculty members and will provide the following feedback and instructions on how to prepare their presentation for our meeting:

- 1. Faculty are given the overall program learning objectives
- 2. Faculty are given the learning objective(s) assigned to their specific topic
- 3. Faculty are asked to
 - summarize the status of the data and our current knowledge on their topic
 - outline the current gaps in our knowledge and/or the data
 - provide recommendations on how to resolve the gaps and bring their topic to conclusion

Intended Audience:

Our audience will consist of physicians in the various branches of interventional cardiology and radiology, endovascular, cardiac and vascular surgery, regenerative medicine and neuroradiology. The estimated number of participants is 80-100.

Our audience selection is in line with the mission of the Society: to foster communication and fellowships between top tier, international investigators, clinicians and Industry Researchers/Developers, in the specialties of interventional radiology, cardiology, surgery, regenerative medicine and neuroradiology who work towards developing and advancing novel products and/or techniques for the treatment of cardiac, vascular and structural diseases. This goal is realized through a regular exchange of ideas between high-level clinical investigators at our biennial meetings during which problems are presented, solutions are offered and innovations are debated. The Clinical Conference Proceedings from the scientific meetings are later published to disseminate the knowledge and conclusions accomplished during the meeting throughout the medical community.

Plans for Evaluating Overall Effective Success of this Program

We will ask all participants to complete and turn in an evaluation form at the end of the program. The evaluation form will assess the following components of our meeting:

- Each of the 11 program sessions will be rated on their content, information and relevancy to the participant's practice
- Overall quality of information
- Was there program bias
- Was the information that the participant gained from attending applicable to his/her practice
- Were the topics presented important to the participant
- Were the participant's knowledge/skills updated
- List the changes that the participant intends to make to his/her clinical practice and/or patient care as a result of the information gained from our meeting
- How well did the program meet the stated objectives
- Was participation by industry appropriate

Overall Program Learning Objectives:

By using evidence based medicine pertinent to patients with coronary artery, structural heart and endovascular diseases, the topics presented during the program will:

- 1. Provide information that will assist in the decision making process relevant to prevention, early identification and referral, and management of patients with these disorders
- 2. Improve the understanding and possible implementation of the latest drug treatments and interventions
- 3. Improve familiarity with current and emerging treatment methods and outcomes in this field

Topic Specific Learning Objectives

Following this program, participants will be able to...

- 1. Discuss the latest advances for the evaluation, management and treatment of structural heart disease including:
 - Transcatheter Aortic Valve Replacement (TAVR) for Aortic Insufficiency and Moderate Aortic Stenosis
 - TAVR Leaflet Degeneration Treatment Strategies
 - Transcatheter Mitral Valve Repair and Replacement
 - Transcatheter Tricuspid Valve Repair and Replacement
 - Interventional Electrocautery for LVOT Obstruction and Hypertrophic Cardiomyopathies
 - LAA Closure
- 2. Discuss the latest advances for the intervention of **coronary and endovascular diseases** including:
 - Applications of Drug Coated Balloon Technologies for de Novo Coronary Artery Lesions
 - Bifurcation Stents and Drug Coated Balloons for Bifurcation Lesions
 - Bioresorbable Scaffolds
 - Chronic Total Occlusions
 - Multivessel PCI in Heat Failure
 - STEMI: Complete Revascularization in Multivessel Disease
 - Strategies to Minimize Infarct Size
 - Endovascular Aneurysm Repair
 - Carotid Interventional Devices
- 3. Discuss the latest advances in <u>imaging & plaque characterization</u> for coronary artery disease including:
 - IVUS, OCT, iFR/FFR
 - Perfusion Imaging
 - Imaging in the future: UHD and 3D Imaging
- 4. Discuss the state of the art studies on **emerging therapies** including:
 - Renal Denervation
 - Translational Research in Interventional Medicine
- 5. Discuss the latest advances on **hemodynamic support** for the cardiac patient including:
 - Hemodynamic Support for Cardiogenic Shock and for High Risk PCI
 - Interventional Devices and Strategies for High Risk PE
- 6. Discuss the current and future direction of healthcare delivery including:
 - a. Applications of Artificial Intelligence in Interventional Medicine
 - b. How to Achieve Health Equity
 - c. Consequences of Public Reporting and Star Ratings

Contact:

Paula Rowbury

Phone: 415-317-4265 / Email: Rowburp.iags@gmail.com